
|Articles|November 13, 2009
Diabetes & Obesity Podcasts: Obesity Drugs and Co-Morbidities
Advertisement
Diabetes & Obesity Series
Obesity Drugs and Co-Morbidities
Subscribe to RSS feed of this series
Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals
Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
4
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
5




